Navigation Links
Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma

he Lymphoma Coalition: www.lymphomacoalition.org <http://www.lymphoma-net.org/>

- Cancer: www.health-kiosk.ch/start_krebs.htm <http://www.lymphomacoalition.org/>

- World Health Organization: www.who.int <http://www.health-kiosk.ch/start_krebs.htm>

<http://www.who.int/>

<http://www.who.int/>

For more information, please contact: <http://www.who.int/>

<http://www.who.int/>

Robert Purcell Amber Bradbury <http://www.who.int/>

Roche Ketchum <http://www.who.int/>

Robert.Purcell@roche.com Amber.Bradbury@Ketchum.com <http://www.who.int/>

+41 61 688 0846 +44 20 7611 3842 Robert.Purcell@roche.com>


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
2. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
3. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
4. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
10. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
11. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
Post Your Comments:
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken ...ADHD within one week, PHILADELPHIA, Oct. 7 /PRNew...HPGY), the global specialty biopharmaceutical comp... September issue of the Journal of,Clinical Psychi...ed,Attention Deficit Hyperactivity Disorder (ADHD)...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aero... safety data from a Phase I trial of its Aerovant,...ty with no evidence of,local irritancy following a..., This 10 mg dose will be the highest of three do...ging study, which is scheduled to begin early,next...
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 1Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 10Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 1Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 2Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 3Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 4Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 5Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 6ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 1ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 2Gender bias may affect care of people with osteoarthritis study finds 13976 1Gender bias may affect care of people with osteoarthritis study finds 13976 2
...7 - Novelos,Therapeutics, Inc. (OTCBB: NVLT), a bi... of therapeutics to treat cancer and,hepatitis, to...na-Farber/Partners Cancer Care (DF/PCC) Phase 2 tr...platinum-resistant ovarian,cancer patients. To dat...or response (assessed at least after 8 weeks / 2,c...
...m versus placebo: - 25,/ - 13 mm Hg (systolic / di...n vaccine dose and induced,antiangiotensin II anti... the Seventeenth European,Meeting on Hypertension ... and MILAN, Italy, June 17, 2007 -,Cytos Biotechno...ta,on its hypertension vaccine CYT006-AngQb at the...
Other Medicine Technology:Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ntists from the University of Cincinnati have come...ood obesity.// This issue has become an important...ety. In the spring season the researchers recruite...m in Meade County, Ky to fight childhood obesity. ...
...rding to the scientist from the Victorian Breast C...east stem cells which have undergone some mutation...ancers.// The Walter and Eliza Hall Institute res...en they found that the breast stem cells do not ex...
...w research conducted by consumer organization Whic...s contain high levels of fat, salt and sugar. Of...hecked for sugar, salt and fat content using the F...three-quarters had a high level of sugars, while a...
...recent announcements by Health Minister, Tony Abbo...ic health enemy No.1, has failed to impress AMA Pr...e initiatives to be much more forceful so that pro... The minister had announced a new ministerial t...
Other Medicine News:Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: